Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:EPIXNASDAQ:PROKNASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.53-4.9%$3.54$2.30▼$8.40$277.57M1.141.79 million shs894,957 shsEPIXESSA Pharma$1.63-1.8%$1.72$1.40▼$9.60$72.35M1.59210,873 shs89,483 shsPROKProKidney$0.95-3.7%$1.51$0.94▼$4.44$277.87M1.38492,563 shs490,830 shsTERNTerns Pharmaceuticals$3.45-5.7%$4.30$3.24▼$11.40$293.04M-0.31.38 million shs812,429 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-4.89%-5.60%-18.65%-43.02%-56.15%EPIXESSA Pharma-1.81%-1.81%+1.24%-0.61%-81.97%PROKProKidney-3.74%-8.39%-38.54%-46.92%-36.06%TERNTerns Pharmaceuticals-5.74%-4.96%-19.77%-48.74%-51.27%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.094 of 5 stars3.51.00.00.02.61.70.6EPIXESSA Pharma3.1262 of 5 stars3.05.00.00.01.72.51.3PROKProKidney1.8732 of 5 stars3.30.00.00.02.72.50.6TERNTerns Pharmaceuticals4.1724 of 5 stars3.32.00.04.12.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$15.80524.51% UpsideEPIXESSA Pharma 2.00Hold$9.50482.82% UpsidePROKProKidney 2.50Moderate Buy$5.00424.82% UpsideTERNTerns Pharmaceuticals 2.67Moderate Buy$18.30430.43% UpsideCurrent Analyst Ratings BreakdownLatest EPIX, ANNX, TERN, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/28/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform12/17/2024ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$2.68 per shareN/APROKProKidneyN/AN/AN/AN/A($4.84) per shareN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%3/25/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.69N/AN/AN/AN/A-24.61%-23.87%5/13/2025 (Estimated)PROKProKidney-$35.47M-$0.55N/AN/AN/AN/AN/A-10.24%3/20/2025 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.18N/AN/AN/AN/A-32.76%-31.33%5/12/2025 (Estimated)Latest EPIX, ANNX, TERN, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2025N/AANNXAnnexon-$0.28N/AN/AN/AN/AN/A3/20/2025N/APROKProKidney-$0.15N/AN/AN/AN/AN/A3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/A2/11/2025Q1 2025EPIXESSA Pharma-$0.18-$0.19-$0.01-$0.19N/AN/A12/17/2024Q4 2024EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18EPIXESSA PharmaN/A33.1233.12PROKProKidneyN/A17.0817.09TERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AEPIXESSA Pharma75.12%PROKProKidney51.59%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%EPIXESSA Pharma15.50%PROKProKidney41.49%TERNTerns Pharmaceuticals15.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionablePROKProKidney3291.66 million170.65 millionOptionableTERNTerns Pharmaceuticals4084.94 million72.11 millionNot OptionableEPIX, ANNX, TERN, and PROK HeadlinesRecent News About These CompaniesTerns Pharmaceuticals (TERN) Expected to Announce Quarterly Earnings on ThursdayMarch 11 at 2:51 AM | americanbankingnews.comThis Weight Loss Stock Could Skyrocket by 462%, According to Wall StreetMarch 9, 2025 | fool.comCandriam S.C.A. Buys New Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)March 8, 2025 | marketbeat.comTerns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Rating of "Moderate Buy" from BrokeragesMarch 5, 2025 | americanbankingnews.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by AnalystsMarch 1, 2025 | marketbeat.comWilliam Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)March 1, 2025 | marketbeat.comTerns Pharmaceuticals initiated with a Market Perform at William BlairMarch 1, 2025 | markets.businessinsider.comWilliam Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform RecommendationMarch 1, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Vericel (VCEL) and Terns Pharmaceuticals (TERN)February 27, 2025 | markets.businessinsider.comIts CEO died. The company scrapped a promising program. Now, for their 2nd act.February 26, 2025 | finance.yahoo.comTerns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)February 26, 2025 | globenewswire.comTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial OfficerFebruary 25, 2025 | finanznachrichten.deTerns Pharmaceuticals sees cash runway into 2028February 25, 2025 | markets.businessinsider.comMizuho Securities Remains a Buy on Terns Pharmaceuticals (TERN)February 25, 2025 | markets.businessinsider.comTerns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare ConferenceFebruary 25, 2025 | globenewswire.comTerns Pharmaceuticals appoints Andrew Gengos as CFOFebruary 24, 2025 | markets.businessinsider.comTerns Pharmaceuticals Appoints Andrew Gengos as Chief Financial OfficerFebruary 24, 2025 | globenewswire.comTerns Pharmaceuticals Appoints Robert Azelby to Board of DirectorsFebruary 20, 2025 | globenewswire.comTerns Pharmaceuticals stock hits 52-week low at $4.16February 13, 2025 | msn.comTerns Pharmaceuticals announces CFO transition and consulting agreementFebruary 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's Swings3 Tech Stocks Defying Sector Weakness and Thriving in 2025By Leo Miller | March 10, 2025View 3 Tech Stocks Defying Sector Weakness and Thriving in 2025GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss TrendsBy Jea Yu | February 12, 2025View GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss TrendsATN International: A Deep Value Play With a High-Powered DividendBy Nathan Reiff | February 17, 2025View ATN International: A Deep Value Play With a High-Powered DividendShopify Confirms Stock Uptrend, New Highs in SightBy Thomas Hughes | February 12, 2025View Shopify Confirms Stock Uptrend, New Highs in SightEPIX, ANNX, TERN, and PROK Company DescriptionsAnnexon NASDAQ:ANNX$2.53 -0.13 (-4.89%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$2.48 -0.05 (-2.17%) As of 03/13/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.ESSA Pharma NASDAQ:EPIX$1.63 -0.03 (-1.81%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$1.62 -0.01 (-0.61%) As of 03/13/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.ProKidney NASDAQ:PROK$0.95 -0.04 (-3.74%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.24%) As of 03/13/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Terns Pharmaceuticals NASDAQ:TERN$3.45 -0.21 (-5.74%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$3.53 +0.08 (+2.32%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Market Overreacts, But Guidewire’s Growth Story Remains Strong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
